UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000002925
Receipt number R000003248
Scientific Title Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.
Date of disclosure of the study information 2009/12/28
Last modified on 2019/07/09 12:48:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.

Acronym

A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy.

Scientific Title

Efficacy of Eplerenone monotherapy and Valsartan monotherapy on patients of Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.

Scientific Title:Acronym

A pilot study to compare efficacy of Eplerenone monotherapy with Valsartan monotherapy.

Region

Japan


Condition

Condition

Subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension.

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A pilot study to assess the clinical utility of Eplerenone monotherapy on subclinical Cushing's syndrome with hypertension and non-functioning adrenocortical adenoma with hypertension by comparing with standard antihypertensive therapy, Valsartan monotherapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase



Assessment

Primary outcomes

Lowering rate of urinary 8-OHdG and urinary 8-Isoprostane from baseline after 6 weeks.

Key secondary outcomes

Lowering rate of blood pressure and CRP from baseline after 6 weeks.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

50mg of Eplerenone monotherapy once daily for 6 weeks on subclinical Cushing's syndrome

Interventions/Control_2

80mg of Valsartan monotherapy once daily for 6 weeks on subclinical Cushing's syndrome

Interventions/Control_3

50mg of Eplerenone monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma

Interventions/Control_4

80mg of Valsartan monotherapy once daily for 6 weeks on non-functioning adrenocortical adenoma

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(a) Patients with hypertension(>=130/80mmHg)
(b)Patients are outpatients or inpatients

Key exclusion criteria

(a) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure.
(b) Patients with aldosterone producing adenoma, Cushing's syndrome and malignant tumor.
(c) Patients who have taken ARB, ACEI, aldosterone antagonist or diuretics therapy.
(d) Patients have contraindication of Eplerenone and Valsartan.
(e) Patients with severe liver damage.
(f) Patients are pregnant or patients breast-feeding, potentially pregnant.
(g) Patients who are diagnosed to be ineligible by the investigator

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kiminori Yamane

Organization

Hiroshima University Hospital

Division name

Department of Endocrinology and Diabetes mellitus

Zip code


Address

1-2-3, Kasumi, Minami-ku, Hiroshima-City, Hiroshima 734-8551, Japan

TEL

082-257-5196

Email



Public contact

Name of contact person

1st name
Middle name
Last name Tsuguka Shiwa

Organization

Hiroshima University Hospital

Division name

Department of Endocrinology and Diabetes mellitus

Zip code


Address

1-2-3, Kasumi, Minami-ku, Hiroshima-City, Hiroshima 734-8551, Japan

TEL

082-257-5196

Homepage URL


Email

tsuguka@hiroshima-u.ac.jp


Sponsor or person

Institute

Hiroshima University Hospital
Department of Endocrinology and Diabetes mellitus

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

None


Other related organizations

Co-sponsor

None

Name of secondary funder(s)

None


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 12 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2009 Year 11 Month 30 Day

Date of IRB

2009 Year 12 Month 01 Day

Anticipated trial start date

2009 Year 12 Month 01 Day

Last follow-up date

2019 Year 07 Month 09 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2009 Year 12 Month 21 Day

Last modified on

2019 Year 07 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003248


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name